The global cardiac arrest treatment market is growing at a significant CAGR of around 5.4% during the forecast period (2020-2026). The market is driven by the significant rise in the incidences of high blood pressure (hypertension) and congestive heart failure. High blood pressure affects approximately one third of the adult population across the globe and is the most common cause of CVD-related mortalities. As per the data published by the American Health Association (AHA) in January 2018, there were 103 million US adults suffering from high blood pressure, which is nearly half of all adults in the US. High blood pressure increases the risk of developing severe conditions including cardiac arrest. Therefore, the market for cardiac arrest treatment is expected to continue growing during the forecast period. 

Increasing work pressure, unhealthy lifestyle such as excessive consumption of alcohol and tobacco, lack of exercise is expected to increase the hypertension patient pool across the globe. According to the World Economic Forum, the loss of work output due to mental health is the highest across the globe. The mental health contributes a huge 35.0% of total work loss due to increasing prevalence of diseases across the globe. The problems related to high BP among the people below the age of 40 years are getting more common, which is increasing the patient pool of hypertension across the globe. It is also expected to create a demand for cardiac arrest treatment globally. However, the adoption of minimally invasive procedures for the treatment of cardiac arrest will affect the market growth during the forecast period.

Segmental Outlook  

The cardiac arrest treatment market is classified on the basis of treatment, which includes drugs and medical devices. The drugs segment is further classified into vasopressors, corticosteroids, anti-arrhythmic drugs, and others.  The medical devices segment in the cardiac arrest market is further sectioned into defibrillators, cardiac resynchronization therapy (CRT), and others. Among drugs and devices, the medical devices are majorly used in the treatment of cardiac arrest. There are several companies across the globe that are offering defibrillators for the treatment of cardiac arrest. In September 2019, Koninklijke Philips N.V. announced the shipment of its two-millionth AED (Automated External Defibrillator).

Global Cardiac Arrest Treatment Market Share by Treatment, 2019 (%)

Regional Outlook 

The global cardiac arrest treatment market is classified on the basis of geography, which includes North America, Europe, Asia-Pacific, and Rest of the World. North America holds a significant share in the global cardiac arrest treatment market. The US plays the critical role in geographic contribution of North America in global cardiac arrest treatment market. Presence of major market players in the US such as Abbott Laboratories, Inc. and ZOLL Medical Corp., and various others is one of the major factors driving global cardiac arrest treatment market. These market players are actively operating in the cardiac arrest treatment market and catering to the needs of advanced treatment solutions in the region. Further, cohesive reimbursement policies for hypertension treatment, rising geriatric population, frequent FDA approvals for drugs, are also expected to drive the drive the growth of the cardiac arrest treatment market in the region.

Global Cardiac Arrest Treatment Market Growth, by Region 2020-2026

Asia-Pacific is expected to propel with a considerable growth rate in the global market

Asia-Pacific is estimated to project a considerable CAGR in the global cardiac arrest treatment market. Countries in Asia-Pacific that are contributing to the market growth include China, India, and Japan. The market in the region is driven by increasing stress and the prevalence of various mental health conditions, such as hypertension. According to the European Society of Cardiology (ESC) in 2018, a report presented by a team of scientists suggested that one in five young adults in India has high blood pressure, which equals to nearly 80 million adults. The major risk factors for high blood pressure is still at its peak, which includes the excessive smoking, tobacco chewing, diabetes mellitus, and high cholesterol. This, in turn, is expected to offer growth opportunity to the cardiac arrest treatment market during the forecast period.

Market Players Outlook

The key players in the cardiac arrest treatment market are contributing significantly by providing advanced technology-based products and through expanding their geographical presence across the globe. The key players operating in the global cardiac arrest treatment market include ZOLL Medical Corp., General Electric Co., Abbott Laboratories, Stryker Corp., Boston Scientific Corp., and Koninklijke Philips N.V. These market players adopt various strategies such as product launch, partnerships, collaborations, merger, and acquisitions to sustain a strong position in the market. For instance, in January 2019, Koninklijke Philips N.V. collaborated with American Heart Association (AHA) for increasing the global survival rates of sudden cardiac arrest. In association with AHA, the company introduced a ‘Connected Pulse’ program that combines education, training, and technology to increase the awareness of cardiopulmonary resuscitation (CPR). This program is expected to escalate the company’s growth and position in the global cardiac arrest treatment market.

The Report Covers

• Market value data analysis of 2019 and forecast to 2026.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global cardiac arrest treatment market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.